ArticlePloS one2026
Symptomatic chikungunya and chronic post-infection arthralgia in a highly endemic setting in Northeastern Brazil, 2018-2019: Clinical characteristics, prevalence and associated factors.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling Clinical Phenotypes in Chronic Chikungunya Disease: Insights from a Brazilian Observational Study.Tropical medicine and infectious disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya, an Aedes-borne disease, poses a significant global health threat due to its substantial morbidity. The prevalence of symptomatic chikungunya virus (CHIKV) infection and chronic arthralgia, as well as their associated factors, vary geographically and across studies. We estimated the prevalence of these outcomes in a household-based survey conducted in a large northeastern Brazilian city (2018-2019) approximately three years after the city's first CHIKV outbreak (2016). Sociodemographic and clinical data were collected through interviews, and arboviruses serostatus (IgG and/or IgM) was determined using ELISA. Arthralgia severity was assessed via Visual Analog Scale (VAS). Prevalence estimates (95% CI) and adjusted prevalence ratios (aPRs) were estimated using Poisson regression with robust variance. Principal Component Analysis (PCA) was used to address multicollinearity and identify latent risk profiles . Of the 760 CHIKV-exposed participants, 70% (95% CI: 66.7-73.2; n = 532) reported symptomatic infections. Among those reporting arthralgia (n = 499), 36.5% (95% CI: 32.4-40.8) experienced symptoms lasting >90 days, and of these, over 70% reported severe pain (VAS ≥ 8). In multivariable analyses, older age (aPR = 1.21 [36-50 years], aPR = 1.19 [51-65 years]), female sex (aPR = 1.19; 95% CI: 1.08-1.32), and prior DENV exposure (aPR = 1.45; 95% CI: 1.03-2.04) were associated with - symptomatic infection, whereas higher income showed a protective association. PCA confirmed these formed distinct risk profiles; a sociodemographic component (older age, prior DENV and single marital status) and a biological sex component each independently increased the odds of symptomatic disease by 31% (aOR=1.31). For chronic arthralgia, risk increased with older age (aPR = 4.60 [51-65 years]), female sex (aPR = 1.70; 95% CI: 1.29-2.25), and severe acute pain (aPR = 2.91; 95% CI: 1.86-4.55), but inversely associated with low income (aPR = 0.67). These findings underscore the need for targeted interventions, particularly for older adults, women, and low-income groups. Further studies are needed to elucidate the immunological mechanisms underlying these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.